In addition, the clinical use of VEGF/VEGFR blockers as anti- angiogenic therapy for patients with advanced NSCLC has been more challenging than anticipated by the preclinical experiments in which long-term benefit of VEGF/VEGFR inhibition was achieved [41]. This evidence concerns the gene KDR and non-small cell lung carcinoma.